Effect of nanocurcumin on serum levels of betatrophin and irisin in patients with metabolic syndrome; a clinical trial

Introduction: Metabolic syndrome is a highly prevalent disease with combination of cardio metabolic risk factors. Insulin resistance the most important reason syndrome. Objectives: The study aimed to evaluate effects nanocurcumin on insulin and serum level irisin betatrophin in patients Patients Methods: Sixty (30 males 30 females) received 80 mg/daily for three months. samples fasting blood were collected at beginning after 90-days intervention measure biomarkers. Results: comparing pre post treatment values revealed significant change plasma glucose (FPG), insulin, homeostasis model assessment (HOMA-IR), (P>0.05), but there was no amount (P>0.05). Conclusion: According results, it seems that use 90 days may have positive some components. However, more studies larger sample sizes are needed confirm findings. Trial registration: trial protocol approved by Iranian Registry Clinical Trials (identifier: IRCT20120215009014N214; https:// www.irct.ir/trial/30187, ethical code; IR.UMSHA.REC.1396.859).